Kodiak Sciences/$KOD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kodiak Sciences
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Ticker
$KOD
Sector
Primary listing
Employees
130
Headquarters
Website
Kodiak Sciences Metrics
BasicAdvanced
$2.3bn
-
-$4.16
2.32
-
Price and volume
Market cap
$2.3bn
Beta
2.32
52-week high
$47.84
52-week low
$3.26
Average daily volume
676k
Financial strength
Current ratio
3.535
Quick ratio
3.42
Long term debt to equity
39.546
Total debt to equity
49.948
Profitability
EBITDA (TTM)
-217.258
Management effectiveness
Return on assets (TTM)
-49.06%
Return on equity (TTM)
-208.80%
Valuation
Price to book
20.04
Price to tangible book (TTM)
20.04
Price to free cash flow (TTM)
-13.572
Free cash flow yield (TTM)
-7.37%
Free cash flow per share (TTM)
-2.669
Growth
Earnings per share change (TTM)
14.80%
3-year earnings per share growth (CAGR)
-11.05%
What the Analysts think about Kodiak Sciences
Analyst ratings (Buy, Hold, Sell) for Kodiak Sciences stock.
Kodiak Sciences Financial Performance
Revenues and expenses
Kodiak Sciences Earnings Performance
Company profitability
Kodiak Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs